C
ancer patients had been reporting problems with cognitive function for years. And for years, clinicians had been stumped about how to handle a problem that has come to be known as chemobrain.
But now, more cancer centers have begun testing interventions for chemobrain, including, most notably, cognitive behavioral therapy (CBT). Major cancer centers in the U.S. and Australia, among others, are now recruiting patients for randomized controlled trials of CBT; five of the trials have 2012 launch dates (see sidebar).
The growing number of trials reflects accumulating data and changing attitudes.
Patricia Ganz, M.D., at UCLA's Jonsson Comprehensive Cancer Center, traces several stages in the evolution of thinking about cancer and cognition. At first, everyone believed that the blood-brain barrier protected patients from chemotherapy, so patient reports were not taken seriously.
As chemotherapy became more common and rigorous, complaints multiplied and researchers began paying attention. Now, more sophisticated imaging methods and animal models have begun to show evidence of brain changes associated with cancer and to suggest mechanisms that could make chemotherapy one of the culprits.
"We are chipping away at getting a scientific database to persuade people," Ganz said.
One addition to that database came in March, with the publication of a small controlled study showing that impaired cognitive function after chemotherapy associated with longitudinal changes in the brain's white matter. Sabine Deprez, M.D., of Belgium's University Hospital Gasthuisberg, and colleagues showed that changes in the white matter associated with neuropsychological test results and with the patients' own reports of specific problems, such as word retrieval. The study appeared in the Journal of Clinical Oncology.
Subjective Versus Objective Cognition
Many chemobrain studies have found no association between patient reports of cognitive problems-"subjective cognition" in psychologists' terms-and the findings of test results, or "objective cogni tion." But Deprez's study found that structural changes in the brain associated with both subjective and objective cognition.
This was "one of the first studies to show that what patients are saying is backed up by test abnormalities," Ganz said. "It shows we have to believe the patient." Heather Green, Ph.D., an Australian investigator, agrees: "The so-called objective tests have their limitations," she wrote in an e-mail from Griffith University in Southeast Queens land. "In a number of circumstances, patients' self-reports of their everyday experiences may be more accurate and more sensitive than what can be detected by our current objective assessment methods."
Green and others say that whether cancer-related cognitive dysfunction is based on standardized test performance or patient reports of dysfunction, it needs to be treated.
Interventions
Treatment research has included some pharmacologic studies, but the drugs tried so far (e.g., modafinil, methylphenidate, donepezil) had mixed results, and studies of cognitive rehabilitation have become more prominent. The first single-arm studies at the beginning of the 2000s were followed by larger trials with waitlist controls (subjects randomized to a waitlist to receive the same intervention later 
